Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30128% above fair value
$42.62+0.05 (+0.12%)
Close on Nov 17, 2026Market cap $49.66BP/E 71.0Yield –
Teva Pharmaceutical Industries revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Teva Pharmaceutical Industries's revenue for the twelve months ending Jun 30, 2026 was $14.10B, down 15.2% year over year. For fiscal 2025 it was $17.26B, up 4.3% from the year before. Over ten years it grew -1.3% a year on average. The highest annual figure on record is $21.90B in fiscal 2016.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.26B | +4.3% |
| FY2024 | Dec 31, 2024 | $16.54B | +4.4% |
| FY2023 | Dec 31, 2023 | $15.85B | +6.2% |
| FY2022 | Dec 31, 2022 | $14.93B | -6.0% |
| FY2021 | Dec 31, 2021 | $15.88B | -4.7% |
| FY2020 | Dec 31, 2020 | $16.66B | -1.4% |
| FY2019 | Dec 31, 2019 | $16.89B | -7.6% |
| FY2018 | Dec 31, 2018 | $18.27B | -16.4% |
| FY2017 | Dec 31, 2017 | $21.85B | -0.2% |
| FY2016 | Dec 31, 2016 | $21.90B | +11.5% |
| FY2015 | Dec 31, 2015 | $19.65B | -3.1% |
| FY2014 | Dec 31, 2014 | $20.27B | -0.2% |
| FY2013 | Dec 31, 2013 | $20.31B | -0.0% |
| FY2012 | Dec 31, 2012 | $20.32B | +10.9% |
| FY2011 | Dec 31, 2011 | $18.31B | +13.6% |
| FY2010 | Dec 31, 2010 | $16.12B | 0.0% |
| FY2009 | Dec 31, 2009 | $16.12B | +45.4% |
| FY2008 | Dec 31, 2008 | $11.09B | +17.8% |
| FY2007 | Dec 31, 2007 | $9.41B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.14B | -0.8% |
| Q1 FY2026 | Mar 31, 2026 | $3.98B | +2.3% |
| Q4 FY2025 | Dec 31, 2025 | $1.50B | -64.5% |
| Q3 FY2025 | Sep 30, 2025 | $4.48B | +3.4% |
| Q2 FY2025 | Jun 30, 2025 | $4.18B | +0.3% |
| Q1 FY2025 | Mar 31, 2025 | $3.89B | +1.9% |
| Q4 FY2024 | Dec 31, 2024 | $4.23B | -5.1% |
| Q3 FY2024 | Sep 30, 2024 | $4.33B | +12.5% |
| Q2 FY2024 | Jun 30, 2024 | $4.16B | +7.4% |
| Q1 FY2024 | Mar 31, 2024 | $3.82B | +4.3% |
| Q4 FY2023 | Dec 31, 2023 | $4.46B | +14.8% |
| Q3 FY2023 | Sep 30, 2023 | $3.85B | +7.1% |
| Q2 FY2023 | Jun 30, 2023 | $3.88B | +2.4% |
| Q1 FY2023 | Mar 31, 2023 | $3.66B | 0.0% |
| Q4 FY2022 | Dec 31, 2022 | $3.88B | -5.3% |
| Q3 FY2022 | Sep 30, 2022 | $3.60B | -7.5% |
| Q2 FY2022 | Jun 30, 2022 | $3.79B | -3.2% |
| Q1 FY2022 | Mar 31, 2022 | $3.66B | -8.1% |
| Q4 FY2021 | Dec 31, 2021 | $4.10B | -7.9% |
| Q3 FY2021 | Sep 30, 2021 | $3.89B | -2.3% |
| Q2 FY2021 | Jun 30, 2021 | $3.91B | +1.0% |
| Q1 FY2021 | Mar 31, 2021 | $3.98B | -8.6% |
| Q4 FY2020 | Dec 31, 2020 | $4.45B | -0.3% |
| Q3 FY2020 | Sep 30, 2020 | $3.98B | -2.8% |
| Q2 FY2020 | Jun 30, 2020 | $3.87B | -7.3% |
| Q1 FY2020 | Mar 31, 2020 | $4.36B | +5.0% |
| Q4 FY2019 | Dec 31, 2019 | $4.47B | +1.1% |
| Q3 FY2019 | Sep 30, 2019 | $4.09B | -6.7% |
| Q2 FY2019 | Jun 30, 2019 | $4.18B | -8.2% |
| Q1 FY2019 | Mar 31, 2019 | $4.15B | -15.6% |
| Q4 FY2018 | Dec 31, 2018 | $4.42B | -18.1% |
| Q3 FY2018 | Sep 30, 2018 | $4.39B | -21.9% |
| Q2 FY2018 | Jun 30, 2018 | $4.55B | -20.4% |
| Q1 FY2018 | Mar 31, 2018 | $4.92B | -13.0% |
| Q4 FY2017 | Dec 31, 2017 | $5.40B | -16.9% |
| Q3 FY2017 | Sep 30, 2017 | $5.62B | +1.0% |
| Q2 FY2017 | Jun 30, 2017 | $5.72B | – |
| Q1 FY2017 | Mar 31, 2017 | $5.65B | – |
| Q4 FY2016 | Dec 31, 2016 | $6.49B | – |
| Q3 FY2016 | Sep 30, 2016 | $5.56B | – |
See a number that looks wrong?